Factors determining the stability, size distribution, and cellular accumulation of small, monodisperse chitosan nanoparticles as candidate vectors for anticancer drug delivery: application to the passive encapsulation of [14C]-doxorubicin

Mas Jaffri Masarudin,Suzanne M Cutts,Benny J Evison,Don R Phillips,Paul J Pigram,Suzanne M. Cutts,Benny J. Evison,Don. R. Phillips,Paul J. Pigram

DOI: https://doi.org/10.2147/NSA.S91785

2019-10-07

Nanotechnology, Science and Applications

Abstract:Mas Jaffri Masarudin, 1 Suzanne M Cutts, 2 Benny J Evison, 3 Don R Phillips, 2 Paul J Pigram 4 1 Department of Cell and Molecular Biology, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, Serdang, Malaysia; 2 Department of Biochemistry, La Trobe University, Melbourne, Victoria, Australia; 3 Department of Chemical Biology and Therapeutics, St Jude Children's Hospital, Memphis, TN, USA; 4 Department of Physics, La Trobe University, Melbourne, Victoria, Australia Abstract: Development of parameters for the fabrication of nanosized vectors is pivotal for its successful administration in therapeutic applications. In this study, homogeneously distributed chitosan nanoparticles (CNPs) with diameters as small as 62 nm and a polydispersity index (PDI) of 0.15 were synthesized and purified using a simple, robust method that was highly reproducible. Nanoparticles were synthesized using modified ionic gelation of the chitosan polymer with sodium tripolyphosphate. Using this method, larger aggregates were mechanically isolated from single particles in the nanoparticle population by selective efficient centrifugation. The presence of disaggregated monodisperse nanoparticles was confirmed using atomic force microscopy. Factors such as anions, pH, and concentration were found to affect the size and stability of nanoparticles directly. The smallest nanoparticle population was ~62 nm in hydrodynamic size, with a low PDI of 0.15, indicating high particle homogeneity. CNPs were highly stable and retained their monodisperse morphology in serum-supplemented media in cell culture conditions for up to 72 hours, before slowly degrading over 6 days. Cell viability assays demonstrated that cells remained viable following a 72-hour exposure to 1 mg/mL CNPs, suggesting that the nanoparticles are well tolerated and highly suited for biomedical applications. Cellular uptake studies using fluorescein isothiocyanate-labeled CNPs showed that cancer cells readily accumulate the nanoparticles 30 minutes posttreatment and that nanoparticles persisted within cells for up to 24 hours posttreatment. As a proof of principle for use in anticancer therapeutic applications, a [ 14 C]-radiolabeled form of the anticancer agent doxorubicin was efficiently encapsulated within the CNP, confirming the feasibility of using this system as a drug delivery vector. Keywords: nanobiotechnology, drug delivery, chitosan, chitosan nanoparticles, doxorubicin, FITC Corrigendum for this paper has been

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is how to prepare small monodisperse chitosan nanoparticles (CNPs) with uniform size, good stability and suitable for anti - cancer drug delivery by optimizing synthesis parameters. Specifically, the authors focus on the following aspects:

1. **Size control of nanoparticles**: How to synthesize chitosan nanoparticles with a diameter of less than 100 nanometers by adjusting reaction conditions (such as pH value, concentration, centrifugation steps, etc.), and ensure that they have a low polydispersity index (PDI) to improve drug loading efficiency and bioavailability.

2. **Stability of nanoparticles**: Study the long - term stability of nanoparticles in the cell culture environment, especially in the medium containing serum, ensure that they can maintain morphological stability within 72 hours and degrade slowly within 6 days, so as to have good biocompatibility and safety.

3. **Cell uptake and toxicity assessment**: Verify whether these nanoparticles can be effectively taken up by cancer cells and evaluate their impact on cell viability, ensure that nanoparticles are non - toxic to cells at high concentrations (such as 1 mg/mL), and are suitable for biomedical applications.

4. **Feasibility of drug delivery system**: By encapsulating the radiolabeled anti - cancer drug [14C] - doxorubicin into nanoparticles, prove the feasibility of this system as a drug delivery carrier. The experimental results show that nanoparticles can efficiently encapsulate drugs and maintain stable drug - release characteristics in the in - vivo environment.

In summary, this study aims to develop a simple and reproducible method to prepare small monodisperse chitosan nanoparticles suitable for anti - cancer drug delivery, and comprehensively evaluate their physicochemical properties, biocompatibility and drug - delivery performance.